ATE432265T1 - Pyrimidinon verbindungen - Google Patents
Pyrimidinon verbindungenInfo
- Publication number
- ATE432265T1 ATE432265T1 AT04077397T AT04077397T ATE432265T1 AT E432265 T1 ATE432265 T1 AT E432265T1 AT 04077397 T AT04077397 T AT 04077397T AT 04077397 T AT04077397 T AT 04077397T AT E432265 T1 ATE432265 T1 AT E432265T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrimidinone compounds
- pyrimidinone
- compounds
- Prior art date
Links
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9910048A GB9910048D0 (en) | 1999-05-01 | 1999-05-01 | Novel compounds |
| GB0002096A GB0002096D0 (en) | 2000-01-28 | 2000-01-28 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE432265T1 true ATE432265T1 (de) | 2009-06-15 |
Family
ID=26243514
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00920741T ATE283845T1 (de) | 1999-05-01 | 2000-04-25 | Pyrimidinon verbindungen |
| AT04077397T ATE432265T1 (de) | 1999-05-01 | 2000-04-25 | Pyrimidinon verbindungen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00920741T ATE283845T1 (de) | 1999-05-01 | 2000-04-25 | Pyrimidinon verbindungen |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6953803B1 (de) |
| EP (2) | EP1175408B1 (de) |
| JP (1) | JP2002543190A (de) |
| KR (1) | KR20020012200A (de) |
| CN (1) | CN1286822C (de) |
| AR (1) | AR023777A1 (de) |
| AT (2) | ATE283845T1 (de) |
| AU (1) | AU766003B2 (de) |
| BR (1) | BR0010220A (de) |
| CA (1) | CA2371671A1 (de) |
| CO (1) | CO5170521A1 (de) |
| CZ (1) | CZ20013904A3 (de) |
| DE (2) | DE60042286D1 (de) |
| DK (1) | DK1175408T3 (de) |
| ES (1) | ES2233361T3 (de) |
| HK (1) | HK1044757B (de) |
| HU (1) | HUP0201122A3 (de) |
| IL (1) | IL146210A0 (de) |
| MX (1) | MXPA01011186A (de) |
| MY (1) | MY136037A (de) |
| NO (1) | NO20015329D0 (de) |
| NZ (1) | NZ515137A (de) |
| PE (1) | PE20010070A1 (de) |
| PL (1) | PL351690A1 (de) |
| PT (1) | PT1175408E (de) |
| SI (1) | SI1175408T1 (de) |
| TR (1) | TR200103216T2 (de) |
| UY (1) | UY26132A1 (de) |
| WO (1) | WO2000066567A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0010220A (pt) * | 1999-05-01 | 2002-05-14 | Smithkline Beecham Plc | Compostos de pirimidinona |
| SI1686119T1 (sl) | 2000-02-16 | 2009-12-31 | Smithkline Beecham Plc | Derivati pirimidin-5-ona kot inhibitorji ldl-pla2 |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| WO2005003118A1 (de) * | 2003-07-02 | 2005-01-13 | Bayer Healthcare Ag | Amid-substituierte 1,2,4-triazin-5 (2h)-one zur behandlung von chronisch inflammatorischen krankheiten |
| US7741020B2 (en) | 2004-04-16 | 2010-06-22 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| DE102004061006A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Benzylthio-1,2,4-triazin-5(2H)-one |
| DE102004061009A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
| CN1954826A (zh) * | 2005-10-26 | 2007-05-02 | 上海生物芯片有限公司 | 银杏叶提取物在降低胆固醇方面的用途 |
| MX2009012197A (es) | 2007-05-11 | 2010-01-15 | Univ Pennsylvania | Metodos para tratamiento de ulceras en la piel. |
| ES2540933T3 (es) | 2007-05-11 | 2015-07-14 | Thomas Jefferson University | Métodos de tratamiento y prevención de enfermedades y trastornos neurodegenerativos |
| AR081399A1 (es) * | 2010-05-17 | 2012-08-29 | Glaxo Group Ltd | Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos. |
| CN104478812A (zh) * | 2010-12-06 | 2015-04-01 | 葛兰素集团有限公司 | 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 |
| JP5886310B2 (ja) | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドGlaxo Group Limited | Lp−PLA2により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
| JP2013545792A (ja) | 2010-12-17 | 2013-12-26 | グラクソ グループ リミテッド | 眼疾患の処置および防止方法 |
| WO2013000108A1 (zh) * | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
| CA2842965A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
| JP2014521625A (ja) | 2011-07-27 | 2014-08-28 | グラクソ グループ リミテッド | 二環式ピリミドン化合物 |
| SG11201401531RA (en) * | 2011-11-11 | 2014-07-30 | Pfizer | 2-thiopyrimidinones |
| BR112015017397A2 (pt) | 2013-01-25 | 2017-07-11 | Glaxosmithkline Ip Dev Ltd | compostos pirimidona bicíclica como inibidores de lp-pla2 |
| KR20150111356A (ko) | 2013-01-25 | 2015-10-05 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화합물 |
| JP6306053B2 (ja) | 2013-01-25 | 2018-04-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 2,3−ジヒドロイミダゾール[1,2−c]ピリミジン−5(1H)−オンに基づくリポタンパク質関連ホスホリパーゼA2(Lp−PLA2)阻害剤 |
| US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| US9552473B2 (en) | 2014-05-14 | 2017-01-24 | Microsoft Technology Licensing, Llc | Claiming data from a virtual whiteboard |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
| CN106008362B (zh) * | 2016-05-24 | 2018-08-10 | 杰达维(上海)医药科技发展有限公司 | 一种嘧啶衍生物的制备方法 |
| JP6545747B2 (ja) * | 2017-05-09 | 2019-07-17 | 山田化学工業株式会社 | 色素化合物 |
| EP4056571A4 (de) | 2019-11-09 | 2024-01-24 | Shanghai Simr Biotechnology Co., Ltd. | Trizyklisches dihydroimidazopyrimidonderivat, verfahren zu seiner herstellung, pharmazeutische zusammensetzung und verwendung davon |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| WO2025015951A1 (zh) | 2023-07-17 | 2025-01-23 | 上海枢境生物科技有限公司 | 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1582527A (en) * | 1975-12-29 | 1981-01-07 | Smith Kline French Lab | Pyrimidone and thiopyrimidone derivatives |
| CA2309177A1 (en) * | 1997-11-06 | 1999-05-20 | Stephen Allan Smith | Pyrimidinone compounds and pharmaceutical compositions containing them |
| US6559155B1 (en) * | 1998-08-21 | 2003-05-06 | Smithkline Beecham P.L.C. | Pyrimidinone derivatives for the treatment of atherosclerosis |
| BR0010220A (pt) * | 1999-05-01 | 2002-05-14 | Smithkline Beecham Plc | Compostos de pirimidinona |
-
2000
- 2000-04-25 BR BR0010220-2A patent/BR0010220A/pt not_active IP Right Cessation
- 2000-04-25 PL PL00351690A patent/PL351690A1/xx not_active Application Discontinuation
- 2000-04-25 HK HK02104602.0A patent/HK1044757B/en not_active IP Right Cessation
- 2000-04-25 EP EP00920741A patent/EP1175408B1/de not_active Expired - Lifetime
- 2000-04-25 EP EP04077397A patent/EP1479671B1/de not_active Expired - Lifetime
- 2000-04-25 MX MXPA01011186A patent/MXPA01011186A/es active IP Right Grant
- 2000-04-25 AT AT00920741T patent/ATE283845T1/de active
- 2000-04-25 AU AU41203/00A patent/AU766003B2/en not_active Expired
- 2000-04-25 NZ NZ515137A patent/NZ515137A/en unknown
- 2000-04-25 SI SI200030609T patent/SI1175408T1/xx unknown
- 2000-04-25 JP JP2000615598A patent/JP2002543190A/ja active Pending
- 2000-04-25 ES ES00920741T patent/ES2233361T3/es not_active Expired - Lifetime
- 2000-04-25 CN CNB008094918A patent/CN1286822C/zh not_active Expired - Lifetime
- 2000-04-25 PT PT00920741T patent/PT1175408E/pt unknown
- 2000-04-25 IL IL14621000A patent/IL146210A0/xx unknown
- 2000-04-25 DE DE60042286T patent/DE60042286D1/de not_active Expired - Fee Related
- 2000-04-25 DK DK00920741T patent/DK1175408T3/da active
- 2000-04-25 WO PCT/EP2000/003727 patent/WO2000066567A1/en not_active Ceased
- 2000-04-25 DE DE60016397T patent/DE60016397T2/de not_active Expired - Lifetime
- 2000-04-25 AT AT04077397T patent/ATE432265T1/de not_active IP Right Cessation
- 2000-04-25 TR TR2001/03216T patent/TR200103216T2/xx unknown
- 2000-04-25 KR KR1020017013976A patent/KR20020012200A/ko not_active Ceased
- 2000-04-25 HU HU0201122A patent/HUP0201122A3/hu unknown
- 2000-04-25 CZ CZ20013904A patent/CZ20013904A3/cs unknown
- 2000-04-25 CA CA002371671A patent/CA2371671A1/en not_active Abandoned
- 2000-04-25 US US10/030,661 patent/US6953803B1/en not_active Expired - Lifetime
- 2000-04-27 AR ARP000102001A patent/AR023777A1/es not_active Application Discontinuation
- 2000-04-28 PE PE2000000399A patent/PE20010070A1/es not_active Application Discontinuation
- 2000-04-28 MY MYPI20001870A patent/MY136037A/en unknown
- 2000-04-28 UY UY26132A patent/UY26132A1/es not_active Application Discontinuation
- 2000-04-28 CO CO00030779A patent/CO5170521A1/es not_active Application Discontinuation
-
2001
- 2001-10-31 NO NO20015329A patent/NO20015329D0/no not_active Application Discontinuation
-
2004
- 2004-02-11 US US10/776,876 patent/US7115616B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE283845T1 (de) | Pyrimidinon verbindungen | |
| ATE344248T1 (de) | Antibakterielle verbindungen | |
| CY2015035I2 (el) | Ενωσεις πυριμιδινης | |
| EE200100502A (et) | Ühendid | |
| NO20024127L (no) | Pyrimidin-forbindelser | |
| NO20015536L (no) | FAP-aktiverte anti-tumor-forbindelser | |
| DE60210782D1 (de) | Glukokinase beeinflussende verbindungen | |
| DE60021262D1 (de) | Bizyklische heteroaromatische verbindungen als lh-agonisten | |
| EE200200224A (et) | Uudsed ühendid | |
| ATE283049T1 (de) | Antibakterielle verbindungen | |
| ATE222893T1 (de) | Triazinylaminostilben verbindungen | |
| NO20021503D0 (no) | Kinazolinoner | |
| ATE405580T1 (de) | Antithrombotische verbindungen | |
| DE69914594D1 (de) | Aryl-annellierte azapolycyclische verbindungen | |
| NO20013769D0 (no) | Kalsilytiske forbindelser | |
| NO20021502D0 (no) | Kinazolinoner | |
| DE60132607D1 (de) | Bicyclische heteroaromatische verbindungen | |
| NO20020466L (no) | Kalsilytiske forbindelser | |
| DE60035826D1 (de) | Entfernungsmesser | |
| ATE405574T1 (de) | Aryl-annellierte azapolyzyklische verbindungen | |
| NO20014262D0 (no) | Tiazoloindolinon-forbindelser | |
| ID29984A (id) | Senyawa-senyawa bis-stirilbifenil | |
| SE9901270D0 (sv) | Novel compounds | |
| SE9901117D0 (sv) | Novel compounds | |
| SE9901118D0 (sv) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |